NDATOPICALFOR SOLUTION
Approved
Jun 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SULFAMYLON (mafenide acetate) by Viatris (2) is clinical pharmacology sulfamylon cream, applied topically produces a marked reduction in the bacterial population present in the avascular tissues of second- and third-degree burns. First approved in 1998.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SULFAMYLON (mafenide acetate) is a topical antimicrobial cream applied directly to burn wounds to reduce bacterial populations in avascular tissue of second- and third-degree burns. It works through bacteriostatic action against gram-negative and gram-positive organisms, including Pseudomonas aeruginosa, and is absorbed systemically and metabolized renally. The drug can permit spontaneous healing of deep partial-thickness burns and prevent conversion to full-thickness wounds.
LOE Approaching
Product is in the final stages of patent protection with moderate competitive pressure (30/100), indicating reduced growth investment and potential team consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY SULFAMYLON Cream, applied topically produces a marked reduction in the bacterial population present in the avascular tissues of second- and third-degree burns. Reduction in bacterial growth after application of SULFAMYLON Cream has also been reported to permit spontaneous…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SULFAMYLON offers limited upside growth potential but provides stable, focused experience in specialty burn care and niche market management under Viatris stewardship. Roles will emphasize cost optimization, market access, and maintaining relevance in a declining exclusivity environment rather than launching or scaling.
Worked on SULFAMYLON at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.